NR3C2 and prostate carcinoma: Spironolactone, which is a MR antagonist ( Chen et al., 2020), is approved for the management of heart failure, hypertension, and edema, and due to its role as an antagonist of androgen receptors (Gabbard et al., 2020) and its aldosterone receptor antagonist properties (Aguilar Medina et al., 2022) is also used off‐label to manage conditions such as acne, hidradenitis, androgenetic alopecia, and hirsutism; and there is evidence in favor of its effectiveness in prostate cancer (Bommareddy et al., 2022).